BioCryst Pharmaceuticals, Inc. has joined forces with Er-Kim Pharmaceuticals to bring ORLADEYO® (berotralstat) to the Turkish market, in line with their mission to provide access to the medication for patients worldwide. Er-Kim's expertise in delivering innovative therapies to patients with unmet medical needs makes them an ideal partner for BioCryst. ORLADEYO is a groundbreaking oral therapy specifically designed to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 and above. The medication works by reducing the activity of plasma kallikrein, a key factor in HAE attacks.
Based in Istanbul, Turkey, Er-Kim Pharmaceuticals specializes in collaborating with biopharmaceutical companies to introduce new products into global markets. With their extensive knowledge of rare diseases, they have successfully brought over 70 innovative treatments to patients worldwide. This partnership will enable ORLADEYO to reach HAE patients in Turkey who are seeking life-changing